Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STR-V003 in Healthy Adults
NCT06344975Phase 2Not yet recruiting
- Sponsor
- Starna Therapeutics
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
01
Overview
A Phase 2 trial of STR-V003 in respiratory syncytial virus infection (RSV), sponsored by Starna Therapeutics. Planned start May 2024; status: not yet recruiting.
02
Drugs
STR-V003
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06344975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344975.